DermTech, Inc. - DMTK STOCK NEWS

DermTech (NASDAQ: DMTK) reported findings from a study published in SKIN, indicating that genomic atypia evaluation via the Pigmented Lesion Assay (PLA) may surpass visual assessment in diagnosing melanoma. The study involved 3,418 pigmented lesions and demonstrated that 18.7% of PLA-positive lesions were classified as melanomas. Additionally, the research highlighted a nearly five-fold increase in melanoma detection using PLA over visual methods. The results underscore the potential for early melanoma detection, potentially improving patient outcomes and reducing invasive procedures.

DermTech (NASDAQ: DMTK) announced that its non-invasive genomic patch testing for melanoma has received a recommendation from the National Comprehensive Cancer Network (NCCN). This endorsement recognizes its use in guiding biopsy decisions for melanoma, affirming the test's appropriateness in clinical practice. The NCCN Guidelines® now include genomic patch testing as a valuable tool for early melanoma detection, highlighting its significance in precision dermatology. Key stakeholders, including Dr. Daniel M. Siegel and Dr. Burkhard Jansen, have praised this milestone for its potential impact on patient care.

DermTech, Inc. (Nasdaq: DMTK) has successfully closed its public offering of 4,872,881 shares of common stock, including 635,593 shares from underwriters' options, at $29.50 each. This offering generated $143.7 million in gross proceeds before expenses. Cowen and William Blair were the joint book-running managers, with additional participation from BTIG, Craig-Hallum, and Oppenheimer & Co. The offering was conducted under DermTech's effective shelf registration statement filed with the SEC in September 2020. The proceeds will support DermTech's mission to enhance non-invasive skin genomics and improve dermatological care.

DermTech, Inc. (DMTK) has announced the pricing of its underwritten public offering of 4,237,288 shares at $29.50 per share, aiming for gross proceeds of approximately $125 million. The offering includes a 30-day option for underwriters to purchase an additional 635,593 shares. Proceeds will support the commercialization of clinical tests, accelerate pipeline development, and cover general corporate needs. The offering is expected to close on January 11, 2021. DermTech focuses on precision dermatology through non-invasive skin genomics.

DermTech, Inc. (Nasdaq: DMTK) announced a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold. Proceeds from the offering will fund commercialization of clinical tests, accelerate pipeline development, and cover general corporate purposes. Cowen and William Blair are the joint book-running managers. The offering is subject to market conditions, and a preliminary prospectus will be available at the SEC’s website.

DermTech announces a strategic leadership change, appointing a new CEO to enhance its operational strategy and drive growth. This transition is expected to refresh the company’s vision and operational effectiveness in the competitive dermatological market.

DermTech, Inc. (NASDAQ: DMTK) announced a positive medical benefit policy from Geisinger Health System for its Pigmented Lesion Assay (PLA), a non-invasive test for early melanoma detection. The PLA boasts a 99% negative predictive value, indicating a significantly low chance of missed melanoma diagnoses. The policy stipulates criteria for medical necessity, including lesion characteristics and conditions. DermTech aims to enhance melanoma detection while reducing the need for invasive biopsies, marking a significant step in precision dermatology.

DermTech (NASDAQ:DMTK), a leader in precision dermatology, announced its participation in the ICR Conference 2021 on January 14, 2021, at 10:00 a.m. Eastern time. Interested parties can access a live and archived webcast of the presentation via DermTech’s Investor Relations website for 90 days post-conference. DermTech specializes in non-invasive skin genomics, aiming to enhance diagnosis and treatment procedures while reducing unnecessary surgeries. The company focuses on the early detection of skin cancers and developing customized treatments for inflammatory diseases.

DermTech (NASDAQ: DMTK) announced the topline results from its TRUST Study on the Pigmented Lesion Assay (PLA), confirming a 99.2% negative predictive value (NPV) for melanoma. The study evaluated 1,781 lesions with initial PLA negative tests, with no late-stage melanoma or deaths reported. Of 302 lesions retested, none had clinically obvious melanoma, enhancing confidence in the PLA's efficacy. The findings indicate that the PLA effectively identifies early-stage melanoma, benefiting patient outcomes while reducing unnecessary surgeries.